

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –40000
Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad
Gujarat-380006

Phone: +91-6359637788, **Email:** investor.relations@kashyaptele-medicines.com,

Website: www.kashyaptele-medicines.com

May 29, 2023

To,

BSE Limited

Listing Department

Phiroz Jeejeebhoy Tower,

25th Floor, Dalal Street,

Mumbai – 400 001.

Ref.: BSE Security Code: 531960


Dear Sir/ Madam,

Subject: Submission of “Audited Financial Results” and Auditor’s Report thereon

With reference to above and pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015 (as amended), find enclosed the Audited Financial Results and Statement of Assets and Liabilities of the Company for the Quarter & Financial Year ended March 31, 2023, prepared in accordance with Regulation 33 of the SEBI (LODR) Regulations, 2015 and Companies (Indian Accounting Standards) Rules, 2015 (IND AS) along with the



PARITOSH TRIVEDI
COMPANY SECRETARY & COMPLIANCE OFFICER



Enc. As above

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -400002
Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006
Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com

Website: www.kashyaptele-medicines.com

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2023

(As per Regulation 33 of SEBI (LODR) Regulations, 2015 & Schedule III Companies Act, 2013 read with IND-AS)

INR in Lakhs Except EPS

S.No.	Particulars	Quarter Ended			Year Ended	
		31-03-2023	31-12-2022	31-03-2022	31-03-2023	31-03-2022
		(Refer Note no. 6)	(Unaudited)	(Refer Note no. 6)	(Audited)	(Audited)
I	Revenue from operations	3.85	5.40	4.00	19.65	19.55
II	Other Income	0.00	0.02	0.00	0.02	0.00
III	Total Revenue (I + II)	3.85	5.42	4.00	19.67	19.55
IV	Expenses					
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00
	(d) Employee benefits expense	2.73	2.46	2.30	10.20	9.27
	(e) Finance Cost	0.00	0.00	0.00	0.00	0.00
	(f) Depreciation and amortisation expense	0.00	0.00	0.00	0.00	0.00
	(g) Other expenses	1.73	2.88	14.85	9.05	20.69
	Total expenses	4.46	5.34	17.15	19.25	29.96
V	Profit/(Loss) before exceptional and extraordinary items and tax (III-IV)	(0.61)	0.08	(13.15)	0.42	(10.41)
VI	Exceptional Items	0.00	0.00	(162.46)	0.00	(162.46)
VII	Profit before Extraordinary Items and tax (V - VI)	(0.61)	0.08	(175.61)	0.42	(172.87)
VIII	Extraordinary items	0.00	0.00	0.00	0.00	0.00
IX	Profit/(Loss) Before Tax (VII- VIII)	(0.61)	0.08	(175.61)	0.42	(172.87)
X	Tax Expense :-					
	(a) Current tax	(0.15)	0.02	(0.63)	0.11	0.00
	(b) Tax relating to previous year	0.00	0.00	(0.11)	0.00	(0.11)
	Total Tax Expense	(0.15)	0.02	(0.74)	0.11	(0.11)
XI	Profit / (Loss) for the period from Continuing Operations (IX - X)	(0.46)	0.06	(174.87)	0.31	(172.76)
XII	Profit/(loss) from Discontinuing Operations	0.00	0.00	0.00	0.00	0.00
XIII	Tax Expense of Discontinuing Operations	0.00	0.00	0.00	0.00	0.00
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	0.00	0.00	0.00	0.00	0.00
XV	Profit / (Loss) for the period (XI + XIV)	(0.46)	0.06	(174.87)	0.31	(172.76)
XVI	Share of profit / (loss) of Associates	N.A	N.A	N.A	N.A	N.A
XVII	Minority interest	N.A	N.A	N.A	N.A	N.A
XVIII	Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates	(0.46)	0.06	(174.87)	0.31	(172.76)
XIX	Other Comprehensive Income					
	A. Items that will be/will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00
	B. Income tax relating to items that will be / will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00
	Total comprehensive income for the period (XVIII+XIX)	(0.46)	0.06	(174.87)	0.31	(172.76)
XX	Paid-up Equity Share Capital (Face Value of Rs. 1/- each)	477.22	477.22	477.22	477.22	477.22
XXI	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	0.00	0.00	0.00	(410.24)	(410.56)
XXII	Earnings per equity share:					
	(a) Basic	(0.001)	0.000	(0.366)	0.001	(0.362)
	(b) Diluted	(0.001)	0.000	(0.366)	0.001	(0.362)

*Notes Enclosed

Place : Ahmedabad

Date : May 29,2023

For and on behalf of Board of Directors of
Kashyap Tele - Medicines Limited



Raghav Agrawal
Director & CFO
DIN: 02264149



KASHYAP TELE-MEDICINES LIMITED

CIN: L29110GJ1995PC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –400002
 Corp. Off.: UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006
 Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com
 Website: www.kashyaptele-medicines.com

STATEMENT OF ASSETS AND LIABILITIES AS AT MARCH 31, 2023

	2023	2022
ASSETS		
I. Intangible Assets		
(A) Goodwill	-	-
(B) Patents/Trade Marks	-	-
(C) Software Licenses	-	-
(D) Computer Software	-	-
(E) Other Intangible Assets	-	-
II. Tangible Assets		
(A) Land	-	-
(B) Buildings	-	-
(C) Plant and Machinery	-	-
(D) Furniture and Fixtures	-	-
(E) Motor Vehicles	-	-
(F) Other Tangible Assets	-	-
III. Financial Assets		
(A) Cash and Bank Balances	1,00,000	1,00,000
(B) Loans and Advances	-	-
(C) Investments	-	-
(D) Derivatives	-	-
(E) Other Financial Assets	-	-
Total Assets	1,00,000	1,00,000
LIABILITIES		
I. Equity		
(A) Share Capital	1,00,000	1,00,000
(B) Reserves	-	-
II. Liabilities		
(A) Current Liabilities		
(i) Trade Payables	-	-
(ii) Other Current Liabilities	-	-
(B) Long-Term Liabilities		
(i) Loans and Advances	-	-
(ii) Other Long-Term Liabilities	-	-
Total Liabilities	1,00,000	1,00,000

	
---	---

Notes to Audited Financial Results and Statement of Assets & Liabilities for the quarter and Financial year ended March 31, 2023:

1	The above Audited Financial Results and Statement of Assets & Liabilities of the Company for the quarter and financial year ended 31 st March, 2023 have been reviewed & recommended by the Audit Committee and approved by the Board of Directors in the Meeting held on May 29, 2023.
2	The Statutory Auditors of the Company have carried out an Audit of the above Audited Financial Results and Statement of Assets & Liabilities for the quarter and financial year ended on 31 st March, 2023 in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and have expressed an unmodified audit opinion thereon .
3	Figures pertaining to previous year/periods have been re-grouped and re-arranged wherever necessary.
4	The Company has adopted, Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ('Ind-AS') from 1 st April, 2017 and accordingly these financial results and all the periods presented have been prepared in accordance with the recognition and measurement principles laid down in IND-AS 34 "Interim Financial Reporting" read with relevant rules issued thereunder and the other accounting principles generally accepted in India and discloses the information required to be disclosed in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015 (as amended). Further, all the applicable amendments stated in the Schedule III of the Companies Act , 2013 has also been adopted and presented in the Financial Statements for the period ended 31 st March, 2023.
5	The Company is engaged in single segment therefore has only one reportable segment in accordance with Ind AS 108 'operating segments'.
6	The financial results for the quarter ended 31 st March, 2023 forming part of the statement of Audited Financial Results are the balancing figures between the audited figures in respect of the full Financial Year ended on 31 st March, 2023 and the published year to date figures up to the third quarter of the financial year under review i.e. 31 st December, 2022, which were subject to limited review by the Statutory Auditor's thereon.
7	Pursuant to compliance of SEBI notification No. SEBI/LAD-NRO/GN/2018/1 dated 9 th May, 2018 , a Statement Of Cash Flows for the Financial Year ended 31 st March, 2023 has also been submitted by way of a note as enclosed herewith as Annexure-A to the said notes to Audited Financial Results & Statement of Assets & Liabilities.
8	Pursuant to SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated 26 th November, 2018-"Fund Raising by Issuance of Debt Securities by Large Entities"; the Company do not fall under the category of Large Corporates as per the given applicability framework of the said circular as on 31 st March, 2023.
9	A Copy of the aforesaid financial results is also available on the website of BSE Limited (www.bseindia.com) and on the website of the Company (www.kashyaptele-medicines.com).

Date : May 29,2023

Place : Ahmedabad



For and on behalf of Board of Directors of
For Kashyap Tele - Medicines Limited



Raghav Agrawal
Director & CFO

DIN: 02264149

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -400002

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006

Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com

Website: www.kashyaptele-medicines.com

Cash Flow Statement for the year ended March 31, 2023

(As per Schedule III Companies Act, 2013 and IND-AS)

		INR in Lakhs	
Particulars		For the Year ended 31/03/2023	For the Year ended 31/03/2022
A	Cash flow from operating activities:		
	Profit/(Loss) before tax	0.42	(172.87)
	Adjustments		
	Exceptional items		162.46
	Operating profit before working capital changes	0.42	(10.41)
	Adjustments for changes in working capital :		
	Change in trade receivables	(0.01)	14.43
	Change in other receivables	6.02	(15.06)
	Change in Current Liabilities & other payables	0.35	(0.40)
	Cash flow from/ (used in) operations	6.78	(11.44)
	Income taxes paid	(0.41)	(0.11)
	Net cash flow from/(used in) operating activities	7.19	(11.33)
B	Cash flow from investing activities:		
	Interest received	-	-
	Net cash (used in)/flow from investing activities	0.00	0.00
C	Cash flow from financing activities:		
	Interest paid	-	-
	Net cash (used in)/flow from financing activities:	0.00	0.00
D	Net increase in cash and cash equivalents	7.19	(11.33)
	Cash and cash equivalents at the beginning of the year	2.12	13.45
	Cash and cash equivalents at the end of the year	9.31	2.12

For and on behalf of Board of Directors of
For, Kashyap Tele - Medicines LimitedRaghav Agrawal
Director & CFO
DIN: 02264149Place : Ahmedabad
Date : May 29, 2023



SAREMAL & CO

Chartered Accountants

CA Saremal Shah (Bcom, FCA); CA Pravin Lavana (Bcom, LLB, FCA)

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

To,
The Board of Directors
Kashyap Tele-Medicines Limited

Opinion and Conclusion

We have (a) audited the Financial Results for the year ended 31st March, 2023 and (b) reviewed the Financial Results for the quarter ended 31st March, 2023 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Financial Results for the Quarter and Year Ended 31st March, 2023 of Kashyap Tele-Medicines Limited ("the Company") ("the statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").


(a) Opinion on Annual Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Financial Results for the year ended 31st March, 2023:

- is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the year then ended.

(b) Conclusion on Unaudited Financial Results for the quarter ended 31st March, 2023

With respect to the Financial Results for the quarter ended 31st March, 2023, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below nothing has come to our attention that causes us to believe that the Financial Results for the quarter ended 31st March, 2023, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Financial Results whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Financial Results, including the disclosures, and whether the Annual Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Annual Financial Results of the Company to express an opinion on the Annual Financial Results.

Materiality is the magnitude of misstatements in the Annual Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.



We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



A handwritten signature in blue ink, appearing to be "S. Saremal", written over the stamp.

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -400002

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006

Phone: +91-6359637788. Email: investor_relations@kashyaptele-medicines.com

Website: www.kashyaptele-medicines.com

Date: 29th May, 2023

To,
BSE Limited
Listing Department,
Phiroz Jeejeebhoy Tower,
25th Floor, Dalal Street,
Mumbai-400 001

Scrip Code – 531960

Sub.: Submission of Declaration in respect to 'Audit Report with Unmodified Opinion' for the Annual Audited Financial Results, Statement of Assets and Liabilities & Cash Flow Statement for the Financial Year ended on March 31, 2023.

Dear Sir/Madam,

With references to the above, the Company do hereby declares that the Statutory Auditors of the Company M/s. Saremal & Co., Chartered Accountants (FRN: 109281W), Ahmedabad have expressed an Unmodified Opinion for their Independent Auditor's Report on Audited Financial Results, Statement of Assets and Liabilities & Cash Flow Statement for the Financial Year ended on 31st March, 2023; which are duly considered and approved by the Board of Directors on 29th May, 2023.

You are kindly requested to acknowledge and take the above into your records.

Thanking you.

Yours faithfully,
FOR, KASHYAP TELE-MEDICINES LIMITED



RAGHAV AGRAWAL
DIRECTOR AND CFO
DIN: 02264149

